1 |
Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Kamiya S. 2000. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J. Med. Microbiol. 49: 635-642.
DOI
|
2 |
Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. 2004. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol. Med. Microbiol. 41: 219-226.
DOI
|
3 |
Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. 2013. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host. Microbe. 13: 711-722.
DOI
|
4 |
Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA, et al. 2009. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect. Immun. 77: 1708-1718.
DOI
|
5 |
Rosenblatt JE, Stewart PR. 1975. Anaerobic bag culture method. J. Clin. Microbiol. 1: 527-530.
DOI
|
6 |
Kim H, Kang SS. 2019. Antifungal activities against Candida albicans, of cell-free supernatants obtained from probiotic Pediococcus acidilactici HW01. Arch. Oral Biol. 99: 113-119.
DOI
|
7 |
Wasfi R, Abd El-Rahman OA, Zafer MM, Ashour HM. 2018. Probiotic Lactobacillus sp. inhibit growth, biofilm formation and gene expression of caries-inducing Streptococcus mutans. J. Cell. Mol. Med. 22: 1972-1983.
DOI
|
8 |
Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing of anaerobic bacteria: Informational Supplement M11-S1. Wayne, P.A.: Clinical and Laboratory Standards Institute.
|
9 |
Pratt LA, Kolter R. 1998. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol. Microbiol. 30: 285-293.
DOI
|
10 |
Jaffar N, Ishikawa Y, Mizuno K, Okinaga T, Maeda T. 2016. Mature biofilm degradation by potential probiotics: Aggregatibacter actinomycetemcomitans versus Lactobacillus spp. PLoS One. 11: e0159466.
DOI
|
11 |
Cady NC, McKean KA, Behnke J, Kubec R, Mosier AP, Kasper SH, et al. 2012. Inhibition of biofilm formation, quorum sensing and infection in Pseudomonas aeruginosa by natural products-inspired organosulfur compounds. PLoS One 7: e38492.
DOI
|
12 |
Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Jr., Mowat E, Ramage G, et al. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3: 1494-1500.
DOI
|
13 |
Fischer J, Prosenc MH, Wolff M, Hort N, Willumeit R, Feyerabend F. 2010. Interference of magnesium corrosion with tetrazolium-based cytotoxicity assays. Acta Biomater. 6: 1813-1823.
DOI
|
14 |
Nosyk O, ter Haseborg E, Metzger U, Frimmel FH. 2008. A standardized pre-treatment method of biofilm flocs for fluorescence microscopic characterization. J. Microbiol. Methods 75: 449-456.
DOI
|
15 |
Bundgaard-Nielsen C, Baandrup UT, Nielsen LP, Sorensen S. 2019. The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue. BMC Cancer 19(1): 399.
DOI
|
16 |
Cordeiro RA, Aguiar ALR, Pereira VS, Pereira LMG, Portela FVM, Brilhante RSN, et al. 2019. Sodium butyrate inhibits planktonic cells and biofilms of Trichosporon spp. Microb. Pathog. 130: 219-225.
DOI
|
17 |
Shang H, Sun J, Chen YQ. 2016. Clostridium Butyricum CGMCC0313.1 Modulates lipid profile, insulin resistance and colon homeostasis in obese mice. PLoS One 11: e0154373.
DOI
|
18 |
Gill PA, van Zelm MC, Muir JG, Gibson PR. 2018. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment. Pharmacol. Ther. 48: 15-34.
DOI
|
19 |
Chung PY, Toh YS. 2014. Anti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus. Pathog. Dis. 70: 231-239.
DOI
|
20 |
Seghal Kiran G, Priyadharshini S, Dobson ADW, Gnanamani E, Selvin J. 2016. Degradation intermediates of polyhydroxy butyrate inhibits phenotypic expression of virulence factors and biofilm formation in luminescent Vibrio sp. PUGSK8. NPJ Biofilms Microbiomes 2: 16002.
DOI
|
21 |
Poquet I, Saujet L, Canette A, Monot M, Mihajlovic J, Ghigo JM, et al. 2018. Clostridium difficile Biofilm: Remodeling metabolism and cell surface to build a sparse and heterogeneously aggregated architecture. Front. Microbiol. 9: 2084.
DOI
|
22 |
Pumbwe L, Skilbeck CA, Nakano V, Avila-Campos MJ, Piazza RM, Wexler HM. 2007. Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of Bacteroides fragilis. Microb. Pathog. 43: 78-87.
DOI
|
23 |
Pumbwe L, Skilbeck CA, Wexler HM. 2008. Presence of quorum-sensing systems associated with multidrug resistance and biofilm formation in Bacteroides fragilis. Microb. Ecol. 56: 412-419.
DOI
|
24 |
Jia L, Li D, Feng N, Shamoon M, Sun Z, Ding L, et al. 2017. Anti-diabetic effects of Clostridium butyricum CGMCC0313.1 through promoting the growth of gut butyrate-producing bacteria in type 2 diabetic mice. Sci. Rep. 7: 7046.
DOI
|
25 |
Wexler HM, Tenorio E, Pumbwe L. 2009. Characteristics of Bacteroides fragilis lacking the major outer membrane protein, OmpA. Microbiology 155: 2694-2706.
DOI
|
26 |
Pumbwe L, Ueda O, Yoshimura F, Chang A, Smith RL, Wexler HM. 2006. Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance. J. Antimicrob. Chemother. 58: 37-46.
DOI
|
27 |
Cassir N, Benamar S, La Scola B. 2016. Clostridium butyricum: from beneficial to a new emerging pathogen. Clin. Microbiol. Infect. 22: 37-45.
DOI
|
28 |
Di Martino P. 2018. Extracellular polymeric substances, a key element in understanding biofilm phenotype. AIMS Microbiol. 4: 274-288.
DOI
|
29 |
Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. 2014. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl. Acad. Sci. USA 111: 18321-18326.
DOI
|
30 |
Chen ZF, Ai LY, Wang JL, Ren LL, Yu YN, Xu J, et al. 2015. Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol. 10: 1433-1445.
DOI
|
31 |
Pierce JV, Bernstein HD. 2016. Genomic diversity of enterotoxigenic strains of Bacteroides fragilis. PLoS One 11: e0158171.
DOI
|
32 |
Nakanishi S, Tanaka M. 2010. Sequence analysis of a bacteriocinogenic plasmid of Clostridium butyricum and expression of the bacteriocin gene in Escherichia coli. Anaerobe. 16: 253-257.
DOI
|
33 |
Li S, Konstantinov SR, Smits R, Peppelenbosch MP. 2017. Bacterial biofilms in colorectal cancer initiation and progression. Trends. Mol. Med. 23: 18-30.
DOI
|
34 |
Venter H, Mowla R, Ohene-Agyei T, Ma S. 2015. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front. Microbiol. 6: 377.
DOI
|
35 |
Isono A, Katsuno T, Sato T, Nakagawa T, Kato Y, Sato N, et al. 2007. Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. Dig. Dis. Sci. 52: 2963-2971.
DOI
|
36 |
Jia L, Shan K, Pan LL, Feng N, Lv Z, Sun Y, et al. 2017. Clostridium butyricum CGMCC0313.1 Protects against autoimmune diabetes by modulating intestinal immune homeostasis and inducing pancreatic regulatory T cells. Front. Immunol. 8: 1345.
DOI
|
37 |
Rabizadeh S, Rhee KJ, Wu S, Huso D, Gan CM, Golub JE, et al. 2007. Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm. Bowel Dis. 13: 1475-1483.
DOI
|
38 |
Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, et al. 2006. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. 12: 782-786.
DOI
|
39 |
Zou S, Fang L, Lee MH. 2018. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol. Rep. (Oxf). 6: 1-12.
DOI
|
40 |
Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. 2005. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43: 3380-3389.
DOI
|
41 |
Kemgang TS, Kapila S, Shanmugam VP, Kapila R. 2014. Cross-talk between probiotic Lactobacilli and host immune system. J. Appl. Microbiol. 117: 303-319.
DOI
|
42 |
Caglar E, Kargul B, Tanboga I. 2005. Bacteriotherapy and probiotics' role on oral health. Oral Dis. 11: 131-137.
DOI
|
43 |
FAO/WHO. 2001. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food: Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Rome: Publishing Management Service, Information Division, FAO.
|
44 |
Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, Silva J, Jr. 2000. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. 6: 171-174.
DOI
|
45 |
Wexler HM. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20: 593-621.
DOI
|
46 |
Kaur S, Sharma P, Kalia N, Singh J, Kaur S. 2018. Antibiofilm properties of the fecal probiotic Lactobacilli against Vibrio spp. Front. Cell. Infect. Microbiol. 8: 120.
DOI
|
47 |
Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. 2003. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr. Int. 45: 86-90.
DOI
|
48 |
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 2008. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 27: 104-119.
DOI
|
49 |
Kashiwagi I, Morita R, Schichita T, Komai K, Saeki K, Matsumoto M, et al. 2015. Smad2 and Smad3 Inversely Regulate TGF-beta Autoinduction in Clostridium butyricum-Activated Dendritic Cells. Immunity 43: 65-79.
DOI
|
50 |
Kuroiwa T, Kobari K, Iwanaga M. 1990. [Inhibition of enteropathogens by Clostridium butyricum MIYAIRI 588]. Kansenshogaku Zasshi 64: 257-263.
DOI
|